We are so excited Luke Timmerman recognized Erik Harris, our Chief Commercial Officer and EVP, as a Black Biopharma Industry Leader! Erik has played a key role in building and shaping Ultragenyx and our company culture. His unwavering focus on people, allyship, and the rare disease community shines through every day. Check out the full Timmerman Report article here: https://lnkd.in/eBCC99MK #Ultragenyx #RareDisease #DEIB
Ultragenyx’s Post
More Relevant Posts
-
For generations, Black women have not been equally included in necessary health research, resulting in a lack of information specific to Black women’s health. Now is the time to include Black women in research as we step toward improving cancer outcomes and eliminating disparities. By joining together, we can gain valuable insights into Black women's diverse experiences and health challenges and learn how to deliver culturally competent and effective interventions, treatments, and preventive measures. Here is another take on "The Importance of Diversity in Clinical Trials": https://lnkd.in/eMpzpStY We have to be a part of the change that we want to see in healthcare. After you watch - please consider joining us at VOICES.CANCER.ORG! #ACS #VOICES #100kstrong
WATCH: The Importance of Diversity in Clinical Trials | Essence
essence.com
-
Excited to lead this dinner discussion. If we're all using the same list building DB/Tech, no advantage. Of recent, there has been a wave of startups that aggregate traditional and disparate private company data sources. Over dinner, we'll discuss how we use tech now, and how some of these new tools (Yes, some with AI!) might create an advantage. Dinner attendees encouraged to share their best practices (even if they're analog). https://lnkd.in/ebf-YCwC #dealsourcing #acgnewjersey #CDForumDinner
ACG NJ's CD Forum Dinner is a quarterly dinner meeting/discussion forum for Corporate Development Officers (CDOs) and other M&A, Transactional, and Strategy executives. The next Forum is February 28, 2024, with Patrick Gilligan, VP & New Business Development Director of The Americas at Marubeni America Corporation. Gilligan will lead a group discussion on “New Methodologies in M&A Deal Sourcing”. This event is invitation only. For more information, visit: https://lnkd.in/gkQWc8BD Thank you to our sponsors and committee members! Sponsors: SS&C Intralinks, EisnerAmper, Gibbons P.C. Committee Members: David Blaskey, Avis Budget Group; Brian Buchert, Church & Dwight Co., Inc.; Pierce C., Radius Recycling; Robin Sitver, Tempo Therapeutics; Vinay Torani, Blue Matter; Michael Givner, IMG Business Advisors; Mark Kuehn, The DAK Group
-
-
Co-Owner: Dr. Alkaline Water LLC, Scarjovan Trust Planning Advisor, Urban Development Advisor, Marketing Advisor to Black Owned Media/Digital Outlets
My Florida Green let’s discuss integrating Black Owned Media Outlets and Digital Platforms into your business. Nick Garulay @My Florida Green’s president and chief executive officer
Naples-based My Florida Green wants a say in case over recreational use of marijuana
naplesnews.com
-
Learn from our experts in this published whitepaper focused on the benefits of pharmaceutical #QualityByDesign and considerations for drug-device #CombinationProducts and partnerships. https://bit.ly/2DgwobB
Benefits Of Pharmaceutical Quality By Design (QbD): Considerations For Drug-Device Combination Products And Partnerships
linkedin.com
-
Only 2 weeks away from the most innovative conference for claims and litigation management CLE content and networking. Hope to see you there and at our panel session on April 4th! #CLM2024 #CLMAlliance #ConcreteCancer #ConstructionLaw
Join Segal McCambridge Shareholder Mari Bryn Dowdy and a panel of industry professionals at the 2024 CLM Alliance (Claims and Litigation Management Alliance) Annual Conference in San Francisco, April 2-4, 2024, for the breakout session "A Malignant Malady: Concrete Cancer, a Coverage Case Study." During the session, Mari Bryn and her colleagues will pull from real-life experiences while providing strategies and advice for successfully challenging and defending construction defect claims, including those derived after concrete cancer appeared in over 100 residential and commercial pools in Central Texas in less than five years. This roundtable discussion offers valuable insights from various perspectives involved in such cases. Don't miss out on this opportunity to learn and engage with experts in the field and register now: https://bit.ly/3wNDEuB #CLM2024 #ConcreteCancer #CoverageCaseStudy #SegalMcCambridge
-
-
Owner, A² Pharmacy Solutions LLC | Health Equity Advocate | Content Creator | Pharmacy Practice Innovator
On this last day of Black History Month 2024, I want to thank @samford_snpha for this amazing reel on the work of A² Pharmacy Solutions and the black pharmacy experience. They asked some great questions! Press play to see my responses▶️ If you haven’t already, please take a moment to follow @a2pharmacysolutions and @samford_snpha on Instagram. #a2ps #a2pharmacysolutions #doctorlany #yourfavoritepharmacist #harddrugnames #pharmacytings #pharmacymyway #pharmacy #pharmacists #pharmacybasedclinic #healthequity #healthequitynow #healthequityadvocate
-
Mass Tort & Product Liability Lawyer | Fighting for Justice for Victims of Dangerous Drugs and Defective Products
Is Third Time the charm for J&J? Under J&J's new plan J&J would pay $6.5 Billion to resolve all ovarian cancer cases - approximately 54,000 - via a third bankruptcy filing. As part of the deal J&J said it will set aside a total of $11 billion total to resolve additional claims over the next 25 years. J&J claims 99% of the claims filed against it related to ovarian cancer and that it has resolved 95% of all meso cases. Any remaining meso cases would be resolved outside of the bankruptcy. Under J&J's plan, there would be a July 26th deadline for claimants to vote at which time J&J believes it would have over 75% of claimant supporting the resolution. J&J likely would not have announced this proposal unless it felt confident it had the support of 75% of the claimants. Will J&J be able to reach this threshold to present a pre-packaged bankruptcy to the court? Or will Plaintiffs hold out in hopes of securing a higher award? #joedoeslaw #masstorts #talc
-
In an article spotlighting Cooley LLP's 2023 Life Sciences Group of the Year recognition, Law360 spoke with partners Marc Recht and Chad Shear, as they discussed how the firm's longstanding biotech industry leadership, collaborative workplace culture and breadth of practice play key roles in Cooley's accomplishments across the life sciences ecosystem. Subscribers can read more with the link below. #TeamCooley
Cooley Featured as Law360 Life Sciences Group of the Year – Law360
cooley.com
-
Experienced Data Analyst | Statistical Modeling | Forecasting | Healthcare & Economic Consulting
Interesting insights into the history of the 340B program and how it's being used today.
Rural Referral Center Participation in the 340B Drug Discount Program | Insights | Berkeley Research Group
thinkbrg.com
-
In an article spotlighting Cooley LLP's 2023 Life Sciences Group of the Year recognition, Law360 spoke with partners Marc Recht and Chad Shear, as they discussed how the firm's longstanding biotech industry leadership, collaborative workplace culture and breadth of practice play key roles in Cooley's accomplishments across the life sciences ecosystem. Subscribers can read more with the link below. #TeamCooley
Cooley Featured as Law360 Life Sciences Group of the Year – Law360
cooley.com
Chair of Neurvati Neurosciences , Former CEO at H. Lundbeck A/S
3moNice to see the recognition of Erik Harris’s leadership! Well deserved indeed